Wells Fargo set a $46.00 price target on Teladoc (NYSE:TDOC) in a research report report published on Friday morning. The brokerage currently has a buy rating on the health services provider’s stock.
A number of other equities research analysts also recently weighed in on TDOC. Deutsche Bank started coverage on Teladoc in a report on Friday, December 8th. They set a buy rating and a $39.00 target price for the company. ValuEngine raised Teladoc from a sell rating to a hold rating in a report on Sunday, December 31st. Citigroup started coverage on Teladoc in a report on Thursday, January 4th. They set a buy rating for the company. KeyCorp restated a buy rating and issued a $41.00 price target on shares of Teladoc in a research report on Wednesday, January 10th. Finally, Jefferies Group started coverage on Teladoc in a research report on Friday, January 26th. They issued a buy rating and a $40.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company. Teladoc presently has a consensus rating of Buy and an average target price of $41.67.
Shares of TDOC traded down $2.25 during midday trading on Friday, reaching $39.15. 748,231 shares of the stock were exchanged, compared to its average volume of 826,499. Teladoc has a twelve month low of $22.73 and a twelve month high of $44.65. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.87 and a current ratio of 3.87. The company has a market capitalization of $2,555.48, a P/E ratio of -23.73 and a beta of 0.36.
Teladoc (NYSE:TDOC) last posted its earnings results on Tuesday, February 27th. The health services provider reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.10). Teladoc had a negative return on equity of 20.95% and a negative net margin of 45.77%. The firm had revenue of $77.14 million for the quarter, compared to analyst estimates of $76.14 million. equities research analysts predict that Teladoc will post -1.37 earnings per share for the current fiscal year.
In other Teladoc news, CEO Jason N. Gorevic sold 40,000 shares of Teladoc stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $43.27, for a total value of $1,730,800.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Mark Hirschhorn sold 100,000 shares of Teladoc stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $39.60, for a total value of $3,960,000.00. Following the completion of the transaction, the chief financial officer now owns 98,960 shares in the company, valued at approximately $3,918,816. The disclosure for this sale can be found here. Insiders sold 364,494 shares of company stock worth $14,665,947 in the last 90 days. 4.47% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in TDOC. Raymond James Financial Services Advisors Inc. grew its position in Teladoc by 63.7% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 9,546 shares of the health services provider’s stock valued at $316,000 after acquiring an additional 3,714 shares during the last quarter. New York State Common Retirement Fund grew its position in Teladoc by 33.2% in the third quarter. New York State Common Retirement Fund now owns 90,513 shares of the health services provider’s stock valued at $3,001,000 after acquiring an additional 22,554 shares during the last quarter. Bank of New York Mellon Corp grew its position in Teladoc by 2.3% in the third quarter. Bank of New York Mellon Corp now owns 285,788 shares of the health services provider’s stock valued at $9,474,000 after acquiring an additional 6,396 shares during the last quarter. Russell Investments Group Ltd. grew its position in Teladoc by 7.6% in the third quarter. Russell Investments Group Ltd. now owns 48,941 shares of the health services provider’s stock valued at $1,622,000 after acquiring an additional 3,442 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its position in Teladoc by 119.6% in the third quarter. Ameriprise Financial Inc. now owns 200,848 shares of the health services provider’s stock valued at $6,658,000 after acquiring an additional 109,373 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: “Teladoc (TDOC) Given a $46.00 Price Target at Wells Fargo” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/teladoc-tdoc-given-a-46-00-price-target-at-wells-fargo.html.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.